Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA) recommended granting approval to the breast cancer drug Kisqali ...
With Friday’s ruling by New Jersey District Judge Zahid Quraishi, Novartis joins a growing list of pharmaceutical companies that have failed in their legal challenges to the Inflation Reduction Act. A ...
If approved, Kisqali could nearly double the number of patients eligible for CDK4/6 inhibitor adjuvant therapy,” said Patrick Horber M.D., President, International, Novartis. “Together with the recent ...
Novartis Pharmaceuticals Corp. was sued Thursday in federal court by four female pharmaceutical sales managers who say the company discriminated against them based on their age and gender when they ...
As a host of generics circle the gates, Novartis has lost another bid to waylay MSN Pharmaceuticals’ copycat of the Swiss pharma’s top-selling drug Entresto. In a court decision filed this ...
Novartis is spending $70 million upfront on a small molecule antitumor drug from the Chinese biotech Chengdu Baiyu.
Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. The deal, which features $1.1 billion in milestones, covers the global rights to a small ...
Oct 16 (Reuters) - Novartis (NOVN.S), opens new tab has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by blocking regulators from ...
Swiss drugmaker Novartis is pressuring hospitals to stop making homebrew copies of its life-extending radiation therapies for cancer patients, but doctors say their drugs are safe and that the ...
A federal judge rejected Novartis Pharmaceuticals Corp.’s motion to declare as unlawful the FDA’s approval of a rival version of its heart failure drug Entresto. In the sealed memorandum, the judge ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback